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ABSTRACT: The key role of RNA-binding proteins (RBPs) in regulating post-transcriptional processes and their involvement in 
several pathologies (i.e., cancer and neurodegeneration) have highlighted their potential as therapeutic targets. In this scenario, 
Embryonic Lethal Abnormal Vision (ELAV) or Hu proteins and their complexes with target mRNAs have been gaining growing 
attention. Compounds able to modulate the complex stability could constitute an innovative pharmacological strategy for the treat-
ment of numerous diseases. Nevertheless, medicinal-chemistry efforts aimed at developing such compounds are still at an early 
stage. As part of our ongoing research in this field, we hereby present the rational design and synthesis of structurally novel HuR 
ligands, potentially acting as HuR–RNA interferers. The following assessment of the structural features of their interaction with 
HuR, combining saturation-transfer difference NMR and in silico studies, provides a guide for further research on the development 
of new effective interfering compounds of the HuR–RNA complex. 
RNA is an important regulatory element of many cellular process-
es and, thus, so-called RNA-binding proteins (RBPs), play a 
prominent role in affecting the fate of target messenger RNAs 
(mRNAs) coding for proteins pivotal in key cellular functions.1-5 
Therefore, a dysregulation of RBPs may be related to the patho-
genesis of several diseases.2,4,6 In 2018, the first candidate drug 
targeting RBPs, called H3B-8800, reached the clinical phase for 
the treatment of acute myelogenous leukemia and chronic mye-
lomonocytic leukemia.7 Among RBPs, the family of ELAV (Em-
bryonic Lethal Abnormal Vision) proteins is involved in control-
ling the functional activities of diverse RNA populations. In par-
ticular, HuR regulates splicing, stability and translation of thou-
sands of coding and non-coding RNAs and is therefore considered 
a valid drug target for anticancer therapy.8 HuR is a nuclear pro-
tein but, upon cell stress such as DNA damage, it shuttles into the 
cytoplasm where it regulates the fate of cargo mRNAs and deter-
mines the abundance of the encoded proteins. Over-expression of 
HuR is associated with tumor progression and poor prognosis in 
various cancer types.8 For this reason, compounds able to bind 
HuR and to inhibit the formation of the HuR–RNA complex may 
have anticancer properties. So far, various high-throughput 
screening campaigns afforded several natural products. 9-12 
After studying the concept of druggability of ELAV proteins and 
related complexes with mRNA,13-15 we analyzed the literature 
concerning the main findings on the ELAV–RNA complexes 
from a medicinal-chemistry standpoint and defined the interaction 
features of HuR and a small series of natural products.16,17 In this 
letter, we report on the structure-based design and the synthesis of 
compounds with different “core structures” and the investigation 
of their interactions with HuR using a combination of saturation-
transfer difference (STD)-NMR and in silico studies. While on the 
RNA side the interaction of HuR and RNA is mediated by AU-
rich elements (AREs), on the protein side two consecutive RNA 
recognition motif-type (RRM1 and RRM2) domains are involved; 
these interact directly with target RNAs through highly conserved 
ribonucleoprotein (RNP1 and RNP2) sequences.18,19 For the de-
 sign of new compounds, we focused on a pocket-like region 
hosting small HuR ligands, formed by the two asymmetric units 
of the protein, which belong to RNP1 and RNP2 of RRM1. In-
spection of the cocrystal structure of the HuR RRM1 and RRM2 
domains in complex with the ARE sequence of RNAc-fos (PDB 
code 4ED5), confirms that this region corresponds to binding site 
of RNA uridine residues 8 and 9 (U8-U9)(Figure 1a).  
 
Figure 1. a) HuR–RNA contacts (PDB code 4ED5) for U8-U9. Red lines show side-chain contacts, green lines show main-chain contacts. 
Distances are expressed in Å;20 b) Modification applied to the anchor to increase the predicted affinity. Dashed blue rectangles indicate 
hydrogen-bond acceptors and dashed green rectangles hydrogen-bond donors on both the original and modified anchor, while the dashed 
orange circle shows the anchor modification potentially allowing for additional hydrophobic interactions with the selected Tyr63 residue. 
 
We based our search for new scaffolds for HuR ligands on the key 
interactions shown in Figure 1a and employed the free web-based 
virtual screening platform AnchorQueryTM.21-24 This program is 
specifically designed for targeting protein–protein interactions 
(PPIs) with small molecules by combining the anchor concept 
with one-pot multicomponent reaction (MCR) chemistry. Briefly, 
PPI inhibitors are characterized by specific moieties able to mimic 
amino acid side chains of the donor protein, called “anchor mo-
tifs”. Since the contact surfaces involved in PPIs are typically 
large and flat, similar to protein–RNA interactions, we used Nu-
cleoQuery, a nucleoside derivative of the web application An-
chorQueryTM for the rational structure‐based design of HuR–RNA 
targeting compounds. We selected U8 and U9 as anchors, and 
investigated whether one of the two nucleotides may be a phar-
macophore in terms of occupied position and interactions. To 
increase the probability of discovering new ligands, the anchors 
were modified so as to bear an additional phenyl group to estab-
lish a π–π-stacking interaction with Tyr63 (Figure 1b). As a result 
of four runs in NucleoQuery, a large library (800 molecules) 
featuring a wide range of structurally diverse derivatives was 
obtained. To select the candidates for synthesis, we relied on 
visual inspection and molecular-recognition studies. This way, we 
selected 17 compounds featuring piperidinones, aromatic hetero-
cycles, N,N-disubstituted amides and sulfonamides as scaffolds 
(see SI, S1.2). For all compounds, the anchor shows good overlap 
with the corresponding uracil ring, preserving the same hydrogen 
bonds with Arg97 and Lys92, while the additional aromatic rings 
should afford the desired interaction with Tyr63. Moreover, se-
lected compounds are engaged in additional interactions with the 
protein, including hydrophobic interactions with residues Ile23, 
Asn25, Phe65, Ile103, Ile133 (docking poses of exemplary com-
pounds for each scaffold can be found in SI, S1.3). Taking into 
account the synthetic feasibility and commercial availability of 
the corresponding starting materials, we selected the most promis-
ing scaffolds and replaced the uracil moiety withan easy-to-handle 
starting material. We evaluated several hydrophobic/aromatic 
portions as anchors, potentially able to interact with HuR in the 
position occupied by U8 and preserving its main contacts. Thus, 
we designed and synthesized compounds 1–4 (Figure 2), charac-
terized by different scaffolds. 
 
   
Figure 2. Structures of the four compounds selected for the exper-
imental study. The modified anchors are highlighted in light blue. 
The different scaffolds (piperidinones, heterocycles, N,N-
disubstituted amides) are highlighted in bold. 
The computationally predicted structures can be easily prepared 
by a short synthesis using MCR or equally efficient processes. 
Thus, compound 1 was synthesized by a Castagnoli-Cushman 
reaction (CC-3CR)25 followed by amidation; 2 by a Groebke-
Blackburn-Bienaymé (GBB-2CR);26 3 by a Van Leusen reaction 
(vL-3CR),27 and 4 by a reductive amination28 followed by acyla-
tion. Herein, we will briefly describe the synthetic strategies 
adopted to obtain compounds 1–4. Further details on protocols 
employed and compound characterization are reported in the 
supporting information (SI, S2). 
Amidation of the acid intermediate trans (±)-9 with amine 10  
afforded compound (±)-1 as racemate.29 The key intermediate 
trans 6-oxopiperidine-3-carboxylic acid (9) was obtained in good 
yield and diastereoselectivity, applying a microwave-aided one-
pot CC-3CR on benzaldehyde (6), isobutylamine (7), and glutaric 
anhydride (8) (Scheme 1a).25 A microwave-assisted GBB-
2CR,26,30 involving isocyanide 12, aldehyde 6 and amino-thiazole 
13 produced compound 2. Isocyanide 12 was obtained starting 
from amine 11, which was converted into the corresponding 
formamide and subsequently dehydrated (Scheme 1b). 
  
 
Scheme 1. Synthetic pathways of compounds 1–4. Reagents 
and conditions: a) Compound (±)-1: i) 6, 7, HCOOH, ACN, mw 
120°C, 50 W, 30 min; ii) 8, p-xylene, reflux, 10 h, yield 62%; iii) 
TBTU, DIPEA, THF, rt, 12 h, yield 71%. b) Compound 2: i) 
Ethyl formiate, 10h; ii) TEA, POCl3, DCM, rt, 4 h, yield 62%; iii) 
6, 13, HCOOH, ACN, mw 120°C, 30 min; iv) 12, ZrCl4, 80 °C, 
10 h, yield 21%. c) Compound 3: i) H2O, 30 min; ii) HCl, MTBE, 
30 min; iii) 15, 16 Me3SiCl, ACN, Toluene, N2, 50 °C, 5 h; iv) 14, 
16 h, yield 62%; v) POCl3, triethylamine, THF, 10°C, 45 min, 
yield 85%; vi) 18, 7 dry DMF, rt, 4 h; vii) 17, K2CO3, rt, 72 h, 
yield 15%. 
A vL-3CR27 on commercially available aldehyde 18, isobutyla-
mine (7) and substituted TosMIC derivative 17 led to compound 
3. This MCR allows to access functionally rich imidazoles in a 
single pot via cycloaddition of TosMIC reagents on imines, gen-
erated in situ from an aldehyde and an amine under mildly basic 
conditions. We synthesized 17 starting from p-toluenesulfinic acid 
(14), which afforded the intermediate formamide derivative upon 
reaction with commercially available 3-phenoxybenzaldehyde 
(15), formamide (16) and chlorotrimethylsilane; subsequent dehy-
dration furnished isocyanide 17 (Scheme 1c).31 Compound 4 was 
obtained by reductive amination of aldehyde 20 followed by an 
amide coupling with acid 23 followed by removal of the THP 
protecting groups (Scheme 1d).28 Prior to the interaction study, 
compounds 1–3 were converted into the corresponding hydrochlo-
ride salts, and their solubility in both the buffer and time-ranges 
required for STD-NMR experiments was evaluated. Under these 
conditions, compound 2 proved to be poorly soluble and had to be 
excluded from the interaction study. 
The interaction of compounds 1, 3 and 4 with HuR was studied by 
STD-NMR spectroscopy. This technique, based on the nuclear 
Overhauser effect, is a well-established epitope-mapping method-
ology for studying the target–ligand interactions.32 Briefly, the 
method relies on the selective irradiation of the protein, which 
allows magnetization to be transferred to the bound ligand; the 
observation of the ligand signals in the NMR spectrum provides 
an indication of the interaction. Those ligand protons that are 
nearest to the protein are more likely to become highly saturated, 
and therefore show the strongest signal in the mono-dimensional 
STD spectrum. Therefore, the intensity of the STD signal (ex-
pressed as absolute STD percentage) reflects the proximity of the 
ligand to the protein surface.33-38 The group epitope mapping 
illustrates which chemical moieties of the ligand are key for mo-
lecular recognition in the binding site. The analysis of STD data 
shows that compounds 1 (Figure S3.2.1 and Table S3.2.1), 3 
(Figure S3.2.2 and Table S3.2.2), and 4 (Figure 3 and Table 
S3.2.3) interact with the protein. 
 
Figure 3. STD-NMR spectrum (bottom) and 1H-NMR (top) of 
compound 4. The strong interaction observed for aromatic rings 
A, B and C is evidenced.  
For ligand 1, the isopropyl group shows the strongest interaction 
(0.40 STD %), while the STD signal related to ring B is the least 
intense (0.03 STD %); ring A contributes to the interaction (0.20 
STD %), while the protons of the amino chain (H14, H15 and 
H16) do not give STD signals. The binding of compound 3 to 
HuR is mediated by the pyridone anchor (1.20 STD %) and by the 
isopropyl moiety (0.30 STD %). For compound 4, we observed 
STD signals of similar intensity for the three aromatic rings (0.40 
% for ring A, 0.36 % for ring B and 0.25% for ring C, respective-
ly), suggesting that they are positioned within a protein pocket.  
In parallel, we performed docking studies on the crystal structure 
of HuR RRM1-2 domains according to the approach we pub-
lished.17 We used STD-NMR in combination with in silico studies 
(applied to the “closed” HuR conformations, see SI) to enable a 
more detailed description of the ligand–protein behavior in solu-
tion. Molecular docking simulations were performed to elucidate 
the binding mode and the interactions between compounds 1, 3, 
and 4 with HuR protein, using Maestro tools39. We observed that 
the anchor moiety of each compound is predicted to be superim-
posed with U8, establishing pivotal interactions with the HuR 
protein. The interactions of compounds 1 and 3 with HuR is de-
scribed in the SI (Section S4.3, Figures S4.3.1 and S4.3.2). As for 
compound 4, we report strong hydrophobic interactions for all 
aromatic rings as evidenced by STD data. The amide carbonyl 
group establishes double hydrogen bonds with Arg97 and hydro-
phobic interactions with the same residue and Ile103 (Figure 4). 
Regarding ring B, it establishes a π–π-stacking interaction with 
 Phe65 and hydrophobic interactions with Arg97, Pro98 and 
Phe65. Ring C is involved in a double hydrogen bond with 
Arg153 and Ile103 and different hydrophobic interactions. The 
zoomed-in view in Figure 4 highlights the full overlap of U8 and 
the anchor motif (ring A) of compound 4.  
 
Figure 4: 3D representation of HuR–4 interactions. Hydrogen 
bonds and hydrophobic interactions are displayed as yellow and 
dark dashed lines, respectively; a π–π-stacking interaction is 
shown as a blue dashed line. RNA and HuR are represented as a 
brown and yellow cartoon, respectively. Compound 4 is shown in 
green sticks. 
In this letter, we report for the first time on the structure-based 
design and synthesis of potential HuR ligands. The structure-
based design strategy used in the present study enabled the identi-
fication of three novel compounds that interact with HuR, estab-
lishing contacts with the RNP regions of RRM1 and RRM2 do-
mains of the protein. Targeting this region is pivotal for the inhi-
bition of the protein activity and so the identification of com-
pounds able to bind to this site plays a critical role in the devel-
opment of new potential HuR inhibitors. Biophysical experiments 
(STD-NMR) are in agreement with computational results, con-
firming that the designed compounds 1, 3, and 4 are indeed bind-
ers of HuR. Furthermore, theoretical experiments carried out by 
molecular dynamics and docking studies confirm that compound 
4 is the best binder of HuR protein, in terms of theoretical binding 
affinity (SI, S4.2). The identified hit compounds will be further 
optimized in forthcoming studies, building an in silico focused 
library. Our findings represent a step forward in discovering novel 
compounds potentially useful to counteract several pathologies 
such as cancer, inflammation, and neurodegeneration, in which 
ELAV–RNA complexes play a pivotal role. 
Experimental Procedures 
Design of new scaffolds. We report all protocols in the SI, S1. 
Compound synthesis. Procedures are reported in the SI, S2. 
Protein expression and purification. HuR aliquots utilized in the 
STD-NMR study were prepared as already described.10,40 
Interaction study with HuR. STD-NMR experiments, Molecular 
dynamics simulations and docking studies were carried out as 
reported in the SI (S3 and S4, respectively). 
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